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Summary  Tendons  and  ligaments  are  dense  ﬁbrous  bands  of  connective  tissue  that  inte-
grate musculoskeletal  components  in  vertebrates.  Tendons  connect  skeletal  muscles  to  the
bone and  function  as  mechanical  force  transmitters,  whereas  ligaments  bind  adjacent  bones
together to  stabilize  joints  and  restrict  unwanted  joint  movement.  Fibroblasts  residing  in  ten-
dons and  ligaments  are  called  tenocytes  and  ligamentocytes,  respectively.  Tenomodulin  (Tnmd)
is a  type  II  transmembrane  glycoprotein  that  is  expressed  at  high  levels  in  tenocytes  and  lig-
amentocytes,  and  is  also  present  in  periodontal  ligament  cells  and  tendon  stem/progenitor
cells. Tnmd  is  related  to  chondromodulin-1  (Chm1),  a  cartilage-derived  angiogenesis  inhibitor,
and both  Tnmd  and  Chm1  are  expressed  in  the  CD31− avascular  mesenchyme.  The  conserved  C-
terminal hydrophobic  domain  of  these  proteins,  which  is  characterized  by  the  eight  Cys  residues
to form  four  disulﬁde  bonds,  may  have  an  anti-angiogenic  function.  This  review  highlights  the
molecular  characterization  and  function  of  Tnmd,  a  speciﬁc  marker  of  tendons  and  ligaments.
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1. Introduction
Tendons  act  as  transmitters  of  muscular  force  and  also
provide  mechanical  energy  storage  via  reversible  stretching
of  collagen  ﬁbers  [1].  Ligaments,  along  with  the  capsule,
seal  the  joint  space  to  prevent  loss  of  synovial  ﬂuid,  which
lubricates  the  articular  surfaces,  and  connect  one  bone  to
another  to  stabilize  synovial  joints  by  limiting  their  move-
ment  [2].  In  the  musculoskeletal  system,  mechanical  energy
generated  from  a  muscle—tendon  unit  is  used  for  locomo-
tion,  and  is  stored  during  deformation  of  ligaments  and
the  capsule  (Fig.  1).  The  stored  energy  is  then  transferred
back  to  the  skeletal  muscle  through  the  tendon  [3].  Tendons
and  ligaments  in  the  craniofacial,  axial,  and  appendicular
regions  are  speciﬁcally  marked  by  tenomodulin  (Tnmd),  a
type  II  transmembrane  glycoprotein  [4—6].
Tendons  and  ligaments,  together  with  fascia  of  the  skele-
tal  muscle,  aponeuroses,  and  the  sclera  and  cornea  of  the
eye,  are  classiﬁed  as  dense  ﬁbrous  connective  tissue.  Such
tissue  consists  of  cells,  collagen,  elastic  ﬁbers,  proteogly-
cans,  and  water.  Collagen  is  the  most  abundant  extracellular
matrix  protein  involved  in  integration  of  musculoskeletal
components.  Tendons  and  ligaments  are  primarily  composed
of  type  I  collagen,  which  provides  mechanical  stability  and
elastic  energy  storage,  but  also  contain  small  amounts  of
types  III  and  V  collagen  [3].  Other  collagens  such  as  types
II,  VI,  XI,  XII,  and  XIV  are  localized  to  ﬁbrocartilage  at  the
entheseal  junction  with  bone,  but  are  not  present  in  the
midsubstance  of  the  tendon  [7,8].  The  highly  aligned  colla-
gen  ﬁbers  of  tendons  are  arranged  along  the  long  axis.  In
contrast  to  other  vascular  rich  mesenchymal  tissues  such  as
bone,  skeletal  muscle,  and  adipose  tissue,  tendons  and  liga-
ments  have  low  vascularity  and  exhibit  a  limited  distribution
of  blood  vessels  [8].
In  the  early  stages  of  musculoskeletal  development,
progenitors  of  musculoskeletal  components  migrate  and  set-
tle  down  in  prospective  regions  to  give  rise  to  cartilage,
muscle,  tendon,  and  ligament  primordia  [9].  Each  muscu-
loskeletal  primordium  initially  develops  as  an  independent
component,  but  later  in  development  tendons  and  ligaments
integrate  each  component  into  a  single  functional  locomo-
tive  organ  (Fig.  2).  The  tendon  progenitor  cell  population  is
marks  the  progenitor  cells  of  tendons  and  ligaments  in  the
appendicular  and  craniofacial  regions  [5,13—15].
SRY  (sex  determining  region  Y)-box  9  (Sox9),  a  key  reg-
ulatory  transcription  factor  involved  in  chondrogenesis,  is
also  expressed  in  a  subpopulation  of  the  tendon/ligament
cell  lineage  [16,17].  Genetic  lineage  tracing  revealed  that
tenocytes  arise  from  both  Scx+/Sox9+ and  Scx+/Sox9− proge-
nitors,  whereas  ligamentocytes  are  derived  from  Scx+/Sox9+
progenitors  [18,19].  The  Scx+/Sox9+ cell  population  is  also
present  in  hyaline  cartilage  near  tendon/ligament  attach-
ment  sites  [14,18]. Conditional  knockout  studies  using
ScxCre;Sox9ﬂox/ﬂox mice  revealed  that  the  Scx+/Sox9+ cell
population  is  necessary  for  the  establishment  of  junctions
between  hyaline  cartilage  and  tendons/ligaments  [18].
Various  growth  factors  of  the  ﬁbroblast  growth  factor
(FGF)  family  and  transforming  growth  factor  beta  (TGF)
superfamily  are  involved  in  tendon  development  and  subse-
quent  growth  [11]. For  example,  FGF-8  and  FGF-4  positively
regulate  the  expression  of  Scx  in  the  axial  and  limb  tendon
progenitors  of  chicken  embryos  [20,21].  Induction  of  early
progenitors  by  FGF  signaling  is  followed  by  later  recruitment
and  maintenance  of  tendon  progenitors,  mediated  by  TGF
signaling.  Disruption  of  TGF signaling  in  Tgfˇ2−/−;Tgfˇ3−/−
embryos  or  mice  lacking  TGF  ˇ type  II  receptor  (TˇRII−/−)
results  in  the  loss  of  most  tendons  and  ligaments  throughout
the  body,  although  the  initial  induction  of  Scx+ tendon  proge-
nitors  is  not  affected  [22].  Speciﬁcation  of  Scx+/Sox9+ bone
eminence  progenitors  is  also  regulated  by  TGF signaling
[19], whereas  bone  morphogenetic  protein  4  (BMP4)  sup-
plied  from  developing  tendon  is  required  for  differentiation
of  these  progenitors  into  skeletal  eminence-forming  cells
[23].
The  cells  residing  in  fully  formed  tendons  and  ligaments
are  elongated  ﬁbroblasts  called  tenocytes  and  ligamento-
cytes,  respectively.  Tenocytes,  which  reside  between  the
longitudinally  aligned  collagen  ﬁbers,  have  extended  nuclei
and  complex  networks  of  cytoplasmic  processes  that  extend
through  the  extracellular  matrix  and  connect  with  neighbor-
ing  cells  via  gap  junctions,  allowing  cellular  communication
[8]. The  gap  junctions  of  tenocytes  are  composed  of  con-
nexin  32  and  connexin  43  [24,25].  Tnmd,  a speciﬁc  marker
of  mature  tenocytes  and  ligamentocytes,  is  a  type  II  trans-derived  from  the  syndetome,  lateral  plate  mesoderm,  and
neural  crest  [10,11].  The  syndetome  is  a  scleraxis  (Scx)-
positive  subdomain  that  occupies  the  dorsolateral  portion
of  the  sclerotome  to  form  the  axial  skeleton  [12].  Scx  also
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gembrane  protein  related  to  chondromodulin-1  (Chm1),  a
artilage-derived  growth  regulator  [4,6,26].  In  this  review,
e  focus  on  functional  roles  of  Tnmd  in  development,
rowth,  and  maintenance  of  tendons  and  ligaments.
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Figure  1  Schematic  illustration  of  musculoskeletal  components  associated  with  mastication.  Tendons  (T)  of  the  masseter  muscle
(Ma) and  temporal  muscle  (Te)  are  shown.  Temporomandibular  joint  (TMJ)  and  periodontium  of  the  mandibular  ﬁrst  molar  are
enlarged. Su,  suture;  JC,  joint  capsule;  TML,  temporomandibular  ligament;  AT,  articular  tubercle;  MF,  mandibular  fossa;  TB,  temporal
bone; AD,  articular  disc;  Pt,  pterygoid  muscle;  AC,  articular  cartilage;  MC,  mandibular  condyle;  RCT,  retrodiscal  connective  tissue;
E, enamel;  D,  dentin;  DP,  dental  pulp;  Gi,  gingiva;  PDL,  periodontal  ligament;  C,  cementum;  AB,  alveolar  bone.
Figure  2  Schematic  illustrations  of  the  development  of  musculoskeletal  tissues.  (A)  Skeletal  development  of  the  forelimb  of
mouse embryo  from  embryonic  day  11  to  14.  The  regions  undergoing  precartilaginous  condensation  are  surrounded  by  a  dotted
line. (B,  C)  Simpliﬁed  models  of  tendon  (B)  and  ligament  (C)  development.  Tendon  primordia  segregate  into  individual  tendons,
depending on  interactions  with  muscles  (B).  Ligament  primordium  forms  adjacent  to  cartilage  primordium,  in  association  with  joint
formation (C).  CP,  cartilage  primordium;  LP,  ligament  primordium;  MP,  muscle  primordium;  TP,  tendon  primordium.
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mouse Tnmd
human Tnmd
mouse pre-Chm1
human pre-Chm1
––––––––––––MAKNPPENCEG CHILNAEALKSKKICKSLKICGLVFGILALTLIVLFW  48
––––––––––––MAKNPPENCED CHILNAEAFKSKKICKSLKICGLVFGILALTLIVLFW  48
MTENSDKVPITMVGPEDVEFCSPPAYTTVTVKPSGSPTRLLKVGAVVLISGAVLLLFGAI  60
MTENSDKVPIALVGPDDVEFCSPPAYATLTVKPS-SPARLLKVGAVVLISGAVLLLFGAI  59
GSKHFWPEVSKKTYDMEHTFYSNGEKKKIYMEIDPITRTEIFRSGNGTDETLEVHDFKNG 108
GSKHFWPEVPKKAYDMEHTFYSNGEKKKIYMEIDPVTRTEIFRSGNGTDETLENHDFKNG 108
GAFYFWKGNDNHIYNVHYSMSINGKLQDGSMEIDAVNNLETFKMGSGAKEAIEVNDFKNG 120
GAGYFWKGSDSHIYNVHYTMSINGKLQDGSMEIDAGNNLETFKMGSGAEEAIAVNDFQNG 119
mouse Tnmd
human Tnmd
mouse pre-Chm1
human pre-Chm1
YTGIYFVGLQKCFIKTQIKV-IPEFSEPEEEIDE––––NEEITTTFFEQSVIWVPAEKPI 163
YTGIYFVGLQKCFIKTQIKV-IPEFSEPEEEIDE––––NEEITTTFFEQSVIWVPAEKPI 163
ITGIRFAGGEKCYIKAQVKARIPEVGTVTKQSIS-ELEGKIMPVNYEENSLIWVAVDQPV 179
ITGIRFAGGEKCYIKAQVKARIPEVGAVTKQSISSKLEGKIMPVKYEENSLIWVAVDQPV 179
mouse Tnmd
human Tnmd
mouse pre-Chm1
human pre-Chm1
ENRDFLKNSKILEICDNVTMYWINPTLIAVSELQDFEEDGEDLHFPTSEKKGIDQNEQWV 223
ENRDFLKNSKILEICDNVTMYWINPTLISVSELQDFEEEGEDLHFPANEKKGIEQNEQWV 223
KDSSFLS-SKILELCGDLPIFWLKPMYP––KEIQRERREVVRNSAPSTTRRPHSEPRGNA 236
KDNSFLS-SKVLELCGDLPIFWLKPTYP––KEIQRERREVVRKIVPTTTKRPHSGPRSNP 236
mouse Tnmd
human Tnmd
mouse pre-Chm1
human pre-Chm1
VPQVKVEKTRHTRQASEE-–––DLPINDYTENGIEFDPMLDERGYCCIY CRRGNRYCRRV 279
VPQVKVEKTRHARQASEE-–––ELPINDYTENGIEFDPMLDERGYCCIY CRRGNRYCRRV 279
GPGRLSNGTRPNVQDDAEPFNPDNPYHQQEGESMTFDPRLDHEGICCIE CRRSYTHCQKI 296
GAGRLNNETRPSVQEDSQAFNPDNPYHQQEGESMTFDPRLDHEGICCIE CRRSYTHCQKI 296
mouse Tnmd
human Tnmd
mouse pre-Chm1
human pre-Chm1
CEPLLGYYPYPYCYQGGRVICRVIMPCNWWVARMLGRV 317
CEPLLGYYPYPYCYQGGRVICRVIMPCNWWVARMLGRV 317
CEPLGGYYPWPYNYQG CRSACRVVMPCSWWVARILGMV 334
CEPLGGYYPWPYNYQG CRSACRVIMPCSWWVARILGMV 334
mouse Tnmd
human Tnmd
mouse pre-Chm1
human pre-Chm1
the TM domain
*
*
*
the BRICHOS domain
mature Chm1
the Cys-rich region with the hyd rophobic tail
Figure  3  Comparison  of  the  amino-acid  sequences  of  mouse  and  human  Tnmd  and  Chm1  precursor  (pre-Chm1).  The  amino-acid
sequences corresponding  to  the  putative  transmembrane  (TM)  domain  are  underlined.  Asterisks  indicate  the  positions  of  putative
N-glycosylation  sites  (Asn  residues).  The  furin-like  endoprotease  cleavage  site  (Arg-Glu-Arg-Arg)  is  boxed.  The  arrow  indicates  the
cleavage product  that  is  secreted  from  cells  as  mature  Chm1.  The  C-terminal  boxed  area  shows  the  conserved  Cys-rich  region  with
the hydrophobic  tails  of  Tnmd  and  Chm1.  The  connecting  lines  indicate  the  conﬁguration  of  the  intramolecular  disulﬁde  bonds  in
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2. Structure of Tnmd and Chm1
As  shown  in  Fig.  3,  Tnmd  was  identiﬁed  as  a  type  II
transmembrane  glycoprotein  (317  amino  acids)  with  a  char-
acteristic  hydrophobic  domain  homologous  to  Chm1  (120
amino  acids)  at  its  C-terminus  [4,6,26].  It  can  be  detected
by  western  blotting  as  glycosylated  and  non-glycosylated
protein  bands  with  molecular  masses  of  40  and  45  kDa,
respectively  [27,28].
Chm1  was  initially  puriﬁed  from  guanidine  extracts  of
bovine  epiphyseal  cartilage  as  a  growth  and  maturation
factor  for  cultured  chondrocytes  [29,30],  but  was  later  iden-
tiﬁed  as  an  angiogenesis  inhibitor  that  blocks  the  growth  of
vascular  endothelial  cells  [31].  Puriﬁed  recombinant  human
Chm1  protein  inhibits  VEGF-induced  angiogenesis  and  lym-
phangiogenesis  in  corneal  micropocket  assays  as  well  as
tumor  angiogenesis  and  growth  [32,33].
Two  structural  domains  are  distinguished  in  Chm1
(Fig.  4A):  the  N-terminal  hydrophilic  domain  with  N-  and
O-glycosylation  sites  (domain  1,  encoded  by  exon  6  of  the
Chm1  gene),  and  the  remaining  C-terminal  domain.  The
C-terminal  domain  contains  all  eight  Cys  residues  in  the  pro-
tein  (the  Cys-rich  region),  which  form  four  disulﬁde  bridges
m
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ind  are  well  conserved  across  vertebrate  species,  followed
y  the  C-terminal  hydrophobic  tail  (domain  2,  encoded  by
xon  7  of  the  gene)  [34,35]. Systematic  Cys-to-Ser  mutations
nd  deletion  experiments  indicated  that  the  single  disulﬁde-
ridged  cyclic  structure  (Cys83-Cys99)  and  the  C-terminal
ail  (Trp111-Val120)  in  domain  2  represent  the  principal  anti-
ngiogenic  structure  of  Chm1  (Fig.  4B,  upper  diagram)  [36].
o  test  this  idea,  a  synthetic  Chm1  C-terminal  peptide  con-
aining  this  17-membered  cyclic  structure  was  prepared  and
hown  to  clearly  inhibit  VEGF-A-induced  migration  of  cul-
ured  vascular  endothelial  cells  [36]. Tnmd  is  predicted  to
ave  a  similar  but  smaller  13-membered  disulﬁde-bridged
yclic  structure  (Cys280-Cys292)  near  its  C-terminus  (Fig.  3).
 Tnmd  C-terminal  peptide  containing  the  smaller  cyclic
tructure  (Fig.  4B,  lower  diagram)  was  synthesized  and
hown  to  be  anti-angiogenic  as  well  [36].
Human  Chm1  is  biosynthesized  in  cartilage  as  a  type
I  transmembrane  precursor  protein  of  334  amino  acids
Fig.  3).  After  cleavage  at  the  furin  hormone-processing
otif  (Arg-Glu-Arg-Arg),  the  C-terminal  region  (120  amino
cids)  is  secreted  as  the  mature  form  of  Chm1  and  stored  in
he  extracellular  matrix  [30]. No  uncleaved  Chm1  precursor
s  present  in  cartilage.  By  contrast,  Tnmd  does  not  contain
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Figure  4  Characteristic  domain  structures  in  human  Chm1,  and  the  indispensable  anti-angiogenic  structure  in  human  Chm1
and Tnmd.  (A)  White  circles  indicate  the  amino-acid  sequence  of  human  Chm1.  Thick  bars  connecting  Cys  residues  represent
intramolecular  disulﬁde  bonds  predicted  from  the  conﬁgurations  of  disulﬁde  bonds  in  bovine  Chm1.  Putative  glycosylation  sites  and
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The predicted  -helix  and  -sheets  are  also  indicated.  (B)  Compa
ydrophobic  tails  in  Chm1  and  Tnmd.  Conserved  amino-acid  res
 furin  processing  signal.  Surface  labeling  experiments  of
ransfected  COS7  cells  revealed  that  human  Tnmd  is  indeed
xpressed  as  a  type  II  transmembrane  protein,  with  its  C-
erminus  exposed  to  the  exterior  of  the  cell  [26].  However,
mmunohistochemical  studies  indicated  that  the  C-terminal
nti-angiogenic  region  of  Tnmd  is  stored  in  the  extracellular
atrix  of  a  certain  type  of  tendinous  tissue  [37—39].  Thus,
t  remains  unclear  whether  the  C-terminal  part  of  Tnmd  is
ctually  cleaved  out.
Both  Tnmd  and  the  Chm1  precursor  have  a  BRICHOS
omain  characterized  by  a  pair  of  conserved  cysteine
esidues  (Fig.  3).  The  BRICHOS  family  of  proteins  has  ﬁve
embers;  the  other  three  are  BRI2,  which  is  mutated  in
amilial  British  and  Danish  dementia;  CA11,  which  is  involved
n  stomach  cancer;  and  surfactant  protein  C,  which  is
d
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[ of  the  single  disulﬁde-bridged  cyclic  structures  and  C-terminal
s  are  indicated  as  (−).
nvolved  in  respiratory  distress  syndrome  (RDS)  [40,41]. The
iological  role  of  the  BRICHOS  domain  is  not  fully  under-
tood,  although  it  has  been  functionally  implicated  in  the
ost-translational  processing  of  certain  types  of  membrane
roteins  [42].
. Distribution of Tnmd during development
nd postnatal growth
nmd  is  expressed  in  dense  connective  tissue  including  ten-
ons,  ligaments,  fascia  of  skeletal  muscle,  and  the  sclera
nd  cornea  of  the  eye,  all  of  which  are  hypovascular
4,5,18,26,28]. In  the  heart,  Chm1  is  expressed  in  valves
43], whereas  Tnmd  is  localized  to  chordae  tendineae,  which
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Figure  5  Localization  of  Tnmd  and  Chm1.  (A—C)  A  frontal  frozen  section  of  the  autopod  prepared  from  a  Sox9flox/+ mouse  at
E18.5. Tnmd+ (green)  (A,  C)  and  Chm1+ (red)  (B,  C)  regions  were  visualized  by  double  immunostaining  of  the  same  section.  A  merged
image is  shown  in  C.  White  and  yellow  arrows  in  A  indicate  tendons  and  ligaments,  respectively.  Radius  and  ulna  are  indicated  as  ra
and ul,  respectively.  Scale  bars,  500  m.  (For  interpretation  of  the  references  to  color  in  this  ﬁgure  legend,  the  reader  is  referred
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are  similar  to  tendons  that  connect  skeletal  muscles  to  bone
[37—39].  Tnmd  is  also  expressed  in  human  adipose  tissue
[44],  whereas  in  5-month-old  mice  it  is  expressed  at  much
lower  levels  in  subcutaneous  white  adipose  tissue  than  in
tail  tendons  [45].
Type  I  collagen,  a  major  component  of  the  extracellular
matrix  in  ﬁbrous  connective  tissues,  is  distributed  in  both
dense  and  loose  connective  tissues,  but  Tnmd  is  predomi-
nantly  localized  to  dense  connective  tissues  containing  thick
bundles  of  aligned  collagen  ﬁbers  [5].  In  tendons,  elongated
tenocytes  are  aligned  parallel  to  thick  mature  collagen  ﬁbers
to  form  regular  layers,  whereas  oval  tenocytes  are  randomly
distributed  in  the  interlaminar  spaces  [5].  Tnmd  is  expressed
in  elongated  but  not  oval  tenocytes,  suggesting  that  this
molecule  is  a  useful  marker  of  mature  tenocytes  in  vivo.
During  development,  Scx  expression  is  associated  with
formation  of  tendon/ligament  primordium  [13],  whereas
Tnmd  expression  increases  markedly  in  parallel  with  mat-
uration  of  tendons  and  ligaments  [5].  In  the  periodontal
ligament  (PDL)  that  joins  the  cementum  covering  the  root
of  the  tooth  to  the  alveolar  bone,  Scx  expression  is  induced
during  tooth  eruption  after  birth  and  is  signiﬁcantly  upregu-
lated  by  a  tensile  force  [46].  Similarly,  Tnmd  is  expressed
in  the  PDL  of  eruptive  and  post-eruptive  teeth,  where  it
promotes  maturation  or  maintenance  of  the  PDL  by  pos-
itively  regulating  cell  adhesion  [38].  In  contrast  to  other
ligaments  connecting  two  or  more  adjacent  bones,  the  PDL
between  the  tooth  and  the  alveolar  bone  is  well  vascularized
and  has  a  high  level  of  alkaline  phosphatase  (ALP)  activity
[46,47].  In  the  PDL,  Scx  is  expressed  in  ALP-positive  PDL
ﬁbroblasts,  but  is  not  detectable  in  perivascular  cells,  which
are  reported  as  progenitor  cells  that  ultimately  differen-
tiate  into  osteoblasts,  cementoblasts,  and  ﬁbroblasts  [48].
Scx-positive  PDL  cells  contribute  to  the  maintenance  of  the
ligamentous  tissues.
Among  well-vascularized  mesenchymal  tissues  in  the
musculoskeletal  system,  cartilage  expressing  Chm1  is  excep-
tionally  avascular  and  highly  resistant  to  vascular  invasion
[49,50].  Dense  connective  tissue  expressing  Tnmd  is  also
poorly  vascularized  [50].  Tnmd  and  Chm1  are  differen-
tially  expressed  in  the  CD31-negative  avascular  mesenchyme
i
p
m
cn  musculoskeletal  tissue  [50]  (Fig.  5).  In  developing
ttachment  sites  for  tendons  or  ligaments,  Tnmd-  and
hm1-positive  cells  are  derived  from  Sox9+ progenitors
nd  localized  to  tendons/ligaments  and  hyaline  cartilage,
espectively  [18].
.  Anti-angiogenic actions of Tnmd
imilarly  to  Chm1,  Tnmd  inhibits  angiogenesis  both  in  vitro
nd  in  vivo  [34]. The  soluble  form  of  the  C-terminal
ys-rich  domain  of  Tnmd  (116  amino  acids)  inhibits  prolif-
ration,  migration,  and  tube  formation  of  human  umbilical
ein  endothelial  cells  and  retinal  vascular  endothelial  cells
26,28].  When  malignant  melanoma  cells  overexpressing  the
oluble  form  of  Tnmd  are  inoculated  into  syngeneic  mice,
umor  growth  is  signiﬁcantly  suppressed  by  inhibition  of
ngiogenesis  [26].  Although  loss  of  Chm1  or  Tnmd  in  mice
oes  not  cause  any  apparent  angiogenesis  phenotype  dur-
ng  embryonic  development  [39,51], loss  of  Chm1  increases
xpression  of  vascular  endothelial  growth  factor  (VEGF)-A,
ipid  deposition,  and  mineralization  in  the  cardiac  valve  in
ged  animals  [43].  The  local  absence  of  Tnmd  in  the  cardiac
hordae  tendineae  induces  angiogenesis  and  matrix  metal-
oproteinase  activation  [37].  Adenoviral  overexpression  of
he  full  coding  region  of  Tnmd  (317  amino  acids)  does  not
nhibit  either  tube  formation  in  vitro  or  tumor  angiogenesis
n  vivo, suggesting  that  cleavage  of  the  C-terminal  Chm1-like
omain  from  Tnmd  and  subsequent  secretion  are  required
or  the  protein’s  anti-angiogenic  activities  [26].  No  soluble
nmd  is  detected  in  the  conditioned  medium  of  COS7  cells
verexpressing  Tnmd  [26].  Indeed,  in  tissue  extracts  of  ten-
ons  and  eye,  endogenous  Tnmd  proteins  can  be  detected  by
estern  blotting  as  a  double  band  between  ∼40  and  ∼45  kDa
28]. On  the  other  hand,  the  short  form  of  Tnmd  protein  con-
aining  the  C-terminal  hydrophobic  region  is  present  in  the
xtracellular  matrix  of  some  tendons  and  chordae  tendineae
n  the  heart  [37,39]. In  addition,  16  kDa  Tnmd  inhibits  retinal
athological  angiogenesis  in  an  ischemic  retinopathy  mouse
odel  [52]. Thus,  under  some  physiological  and  pathologi-
al  conditions,  the  extracellular  anti-angiogenic  domain  of
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nmd  could  be  cleaved  and  released  from  cells  in  the  soluble
orm  by  ectodomain  shedding,  and  subsequently  modulate
ngiogenesis.
. Role of Tnmd in tenocytes/ligamentocytes
nd tendon stem/progenitor cells
ice  lacking  Tnmd  do  not  have  severe  developmental  phen-
types,  but  they  do  exhibit  reduced  tendon  cell  density,
educed  tenocyte  proliferation,  and  elevated  collagen  ﬁb-
il  size  in  postnatal  tendons  [39].  Similarly  to  Chm1,  which
ynergistically  stimulates  chondrocyte  proliferation  in  the
resence  of  FGF-2  [30],  Tnmd  positively  regulates  teno-
yte  proliferation.  Overexpression  of  Tnmd  in  a  human  PDL
ell  line  positively  regulates  cell  adhesion  to  promote  mat-
ration  and  maintenance  of  the  differentiated  phenotype
38].
Tendons  contain  tendon  stem/progenitor  cells  (TSPCs)
nvolved  in  tissue  homeostasis  and  regeneration  [53,54].
SPCs  contribute  to  the  early  healing  response  in  acute
njuries,  as  well  as  the  ectopic  cartilage/bone  formation
bserved  in  chronic  tendinopathy.  TSPCs  reside  in  a  unique
olecular  niche  composed  of  biglycan  and  ﬁbromodulin,
hich  modulate  BMP  signaling  and  are  critical  for  TSPC
unction  [53,55].  In  comparison  with  human  bone  marrow-
erived  mesenchymal  stem  cells  (BMSCs),  human  TSPCs
xpress  Tnmd  at  a  higher  level  [53].  Ectopic  expression  of
cx  induces  conversion  of  human  BMSCs  into  tendon  progen-
tor  cells  expressing  Tnmd  [56].  In  addition,  BMP-12  induces
cx  and  Tnmd  expression  in  rat  BMSCs  and  mouse  C3H10T1/2
ells  [57,58].
A  recent  study  showed  that  loss  of  Tnmd  does  not  affect
ultipotency  of  Tnmd  KO-derived  TSPCs,  but  instead  results
n  reduced  TSPCs  clonogenicity  and  self-renewal  together
ith  higher  incidence  of  senescence  [59].  Re-expression  of
ither  full-length  Tnmd  or  the  C-terminal  116  amino  acids
n  Tnmd  KO-derived  TSPCs  rescues  the  proliferation  deﬁcit,
uggesting  that  Tnmd  is  required  for  TSPCs  self-renewal
59].
. Tnmd expression during tendon
epair/healing
nce  injured,  repair/healing  of  tendons  or  ligaments  is  a
low  process  due  to  the  hypocellular  nature  of  these  tissues
nd  their  poor  blood  supply  relative  to  well-vascularized
esenchymal  tissues  such  as  bone  and  dermis.  Damaged  or
orn  tendons  or  ligaments  are  often  ﬁlled  with  scar  tissue,
n  which  collagen  ﬁbers  are  more  abundant  and  haphaz-
rdly  arranged.  Therefore,  it  is  challenging  to  develop  a
trategy  for  inducing  complete  regeneration  of  tendons  or
igaments.  To  this  end,  Tnmd  is  a  useful  phenotypic  marker
or  evaluating  maturation  of  tenocytes  and  ligamentocytes
uring  the  healing  process.  In  a  rat  rotator  cuff  healing
odel,  FGF-2  enhances  tendon-to-bone  healing,  a  processn  which  increased  Tnmd  expression  is  correlated  with
ormation  of  tendon-like  reparative  tissues  accompanied
y  extracellular  collagen  ﬁbers  with  aligned  orientations
15].
t
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. Regulation of  Tnmd expression by
ranscription factors
nmd  and  Scx  are  coexpressed  in  developing  tendons  and
igaments  during  development  [5]. In  Scx-null  mice,  Tnmd
xpression  is  not  detected  in  the  developing  tendon  [60].
verexpression  of  Scx  in  developing  chicken  hindlimb  results
n  upregulation  of  Tnmd  in  tenocytes,  although  Scx  does
ot  induce  ectopic  tendon  formation  [5].  Upregulation  of
nmd  is  also  observed  in  cultured  tenocytes  upon  overex-
ression  of  Scx  or  other  b-HLH  transcription  factors  such
s  Paraxis  and  Twist  [45]. By  contrast,  overexpression  of
yogenin,  one  of  the  key  transcription  factors  involved
n  myogenesis,  induces  myogenic  differentiation  in  teno-
ytes  and  dramatic  downregulation  of  Tnmd  expression  [45].
ikewise,  upon  Sox9  overexpression,  Tnmd+ tenocytes  trans-
ifferentiate  into  chondrocytes  expressing  Chm1  but  not
nmd  [45].  Pax1,  a  sclerotomal  marker,  also  downregulates
nmd  expression  in  tenocytes  [5].  Mohawk  (Mkx),  an  atypical
omeodomain-containing  transcription  factor,  is  predomi-
antly  expressed  in  tendons  and  ligaments  [61,62]. In  mice
acking  Mkx, Tnmd  expression  decreases  without  affecting
cx  expression,  suggesting  that  Mkx  is  also  involved  in  reg-
lation  of  Tnmd  expression  [62].  The  low  level  of  Tnmd
xpression  in  BMSCs  increases  when  these  cells  are  cul-
ured  in  collagen  gel  containing  glycogen  synthase  kinase-3
nhibitor  [63],  suggesting  that  Wnt/-catenin  signaling  also
ediates  the  expression  of  Tnmd.  Together,  these  obser-
ations  indicate  that  Tnmd  expression  is  closely  associated
ith  the  differentiation  status  of  cells  in  the  tendon  and  lig-
ment  lineages  and  sensitively  reﬂects  the  maturation  level
f  tenocytes  and  ligamentocytes.
. Conclusions and perspectives
nderstanding  the  molecular  mechanisms  governing  devel-
pment,  growth,  and  maintenance  of  tendons  and  ligaments
s  an  important  step  toward  developing  functional  regener-
tive  therapies  for  these  force-transmitting  tissues,  which
re  often  replaced  by  scar  tissue  after  injury.  Tnmd  is  an
nti-angiogenic  type  II  transmembrane  glycoprotein  with  a
-terminal  Cys-rich  domain  homologous  to  that  of  Chm1.
nmd  speciﬁcally  marks  tendons  and  ligaments  in  the  cra-
iofacial,  axial,  and  appendicular  regions,  and  the  level  of
nmd  expression  is  correlated  with  avascularity  in  tendinous
nd  ligamentous  tissues.  Furthermore,  a  series  of  genetic
tudies  using  Tnmd  knockout  mice  revealed  multiple  func-
ional  roles  of  Tnmd  as  a  positive  regulator  of  postnatal
endon  growth,  maturation  of  collagen  ﬁbers,  and  cellular
dhesion  in  the  PDL,  as  well  as  in  maintenance  of  stemness
n  TSPCs.  During  development  and  growth,  Tnmd  expression
s  positively  regulated  by  Scx  and  increases  in  association
ith  maturation  of  tendons  and  ligaments.  During  the  tis-
ue  repair/healing  process,  Tnmd  expression  is  expressed
t  high  levels  in  mature  tenocytes,  suggesting  that  it  is  an
xcellent  marker  speciﬁc  for  tenocyte  and  ligamentocyte
ifferentiation  from  mesenchymal  stem  cells.  Thus,  func-
ional  repair  of  tendons  and  ligaments  can  be  evaluated  in
erms  of  the  expression  level  of  Tnmd  in  the  healing  tis-
ues.  Screening  of  molecules  that  facilitate  upregulation  of
nmd  during  wound  healing  represents  a  promising  strategy
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for  identifying  agents  for  future  regenerative  therapies  of
tendons  and  ligaments.
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